Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Complete title: A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients with Metastatic Prostate Cancer

Research Study Number 9389
 
Principal Investigator Michael Schweizer
 
Phase I

Research Study Description

The purpose of this study is to determine if a vaccine called pTVG-AR can enhance patients' immune response against prostate cancer.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9389
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Prostate Cancer; Solid Tumors; Urogenital Neoplasms; Genital Neoplasms, Male

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials